Asset Details
Do you wish to reserve the book?
Protein degradation technology: a strategic paradigm shift in drug discovery
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Protein degradation technology: a strategic paradigm shift in drug discovery
Do you wish to request the book?
Protein degradation technology: a strategic paradigm shift in drug discovery
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Protein degradation technology: a strategic paradigm shift in drug discovery
2021
Overview
Targeting pathogenic proteins with small-molecule inhibitors (SMIs) has become a widely used strategy for treating malignant tumors. However, most intracellular proteins have been proven to be undruggable due to a lack of active sites, leading to a significant challenge in the design and development of SMIs. In recent years, the proteolysis-targeting chimeric technology and related emerging degradation technologies have provided additional approaches for targeting these undruggable proteins. These degradation technologies show a tendency of superiority over SMIs, including the rapid and continuous target consumption as well as the stronger pharmacological effects, being a hot topic in current research. This review mainly focuses on summarizing the development of protein degradation technologies in recent years. Their advantages, potential applications, and limitations are also discussed. We hope this review would shed light on the design, discovery, and clinical application of drugs associated with these degradation technologies.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Enzymes
/ Humans
/ Kinases
/ Ligands
/ Medicine
/ molecular engineering for drug discovery
/ Mutation
/ New developments in delivery technology
/ Oncology
/ PROTAC
/ Proteins
/ Proteins - antagonists & inhibitors
/ Review
/ Small Molecule Libraries - chemistry
/ Small Molecule Libraries - pharmacology
/ Tumors
